-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On April 25, Zejing Pharmaceutical issued an announcement stating that recently, its research product Jacketinib Hydrochloride Tablets clinical trial application was approved by the US FDA for the treatment of medium and high-risk myelofibrosis.
Jacketinib Hydrochloride Tablets is a small molecule JAK kinase inhibitor new drug independently developed by Zejing Pharmaceutical, which belongs to the first class of new drugs, and Zejing Pharmaceutical has the independent intellectual property rights of this product.
Jacketinib hydrochloride can inhibit the non-receptor tyrosine Janus related kinases JAK1, JAK2 and JAK3.
Jacketinib hydrochloride can effectively inhibit the activation of JAK signaling pathway and inhibit the phosphorylation of activator of transcription (STAT), thereby inhibiting downstream gene expression regulated by STAT.
The first domestic application for Jectinib hydrochloride tablets was submitted for acceptance in March 2016.